SciClone Pharmaceuticals, Inc. company was founded in 1989 and is headquartered in Foster City, California. SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant. SciClone's products under development includes ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. It also holds Chinese marketing rights from Biocompatibles International plc. for DC Bead, a product for the treatment of liver cancer or hepatocellular carcinoma.

Shanghai Pharmaceutical Group, or SPGC, knows that Big Pharma is big business. One of China's largest pharmaceutical companies, SPGC makes over-the-counter (OTC) medicines, prescription drugs, active pharmaceutical ingredients (APIs), biopharmaceuticals, and traditional Chinese medicine. The vertically-integrated company distributes its wares and owns more than 1,000 retail locations. SPGC sells drugs in 30 countries from five foreign offices. Its R&D facility, Central Research Institute, operates 10 centers across China. In 1996 many small producers, including Sine, Dragon & Tiger, and Pioneer, merged to form SPGC.

Wockhardt works hard in the pharmaceutical world. The research and pharmaceutical manufacturing firm employs more than 500 scientists who focus on recombinant biopharmaceuticals, generics, and new drug discovery. Wockhardt's products include injectables, tablets, liquids, and topicals (creams and ointments) that it manufactures to sell itself and for AstraZeneca, Sanofi-Aventis, Cell Therapeutics, Schering-Plough, and other major drug companies. It operates 15 manufacturing plants in India, the UK, Ireland, France, and the US, and has filed more than 250 patents for biotechnology products. The company is a subsidiary of Khorakiwala Holdings and Investments.

Aradigm Corporation company was founded in 1991 and is based in Hayward, California. Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. Aradigm company's activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), inhalation anthrax infections, and smoking cessation. Its proprietary product candidates under development include ARD-3100 under phase II clinical trial for the treatment of cystic fibrosis; ARD-3150 under phase II clinical trial for the treatment of bronchiectasis; ARD-1600 under phase I clinical trial for the treatment of tobacco smoking cessation; and ARD-1100, a preclinical product for the treatment of inhalation anthrax indications. Aradigm company's collaborative product candidates comprise ARD-1550, a phase II product and ARD-1500, a preclinical stage product for the treatment of pulmonary arterial hypertension; and ARD-1700, a preclinical stage product for the treatment of asthma and COPD. Aradigm Corporation has a collaboration agreement with CyDex Pharmaceuticals, Inc. for the development and commercialization of products to deliver inhaled corticosteroids, anticholinergics, and beta-2 agonists for the treatment of asthma and COPD.

MEDA PHARMACEUTICALS INC. is the U.S. subsidiary of Meda AB. Meda Pharmaceuticals specializes in respiratory, allergy, central nervous system, and cough-cold products. MEDA AB is an international specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company’s strategy. Meda is represented with own organizations in 26 countries and with more than 1,500 employees within marketing and sales. Meda’s products are sold in approximately 120 countries world-wide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange.

AAIPharma provides contract research services to the pharmaceutical, biotech, and medical device industries. Its outsourcing services run the gamut from drug candidate selection and feasibility studies, to bioanalytical testing and clinical trials management. Its early clinical development division helps evaluate potential compounds and design patient studies. The company's clinical development businesses run large clinical trials for customers around the world. Other services include regulatory support and data management. AAIPharma has divested its pharmaceutical development division, which cranked out small batches of drugs to supply clinical trials and develops oral drug delivery technology.

Quantum was founded in 1981. Quantum, Inc. company distributes dozens of natural products to consumers and health food retailers in the US and Canada. Quantum's inventory includes vitamins, insect repellents, and skin care products. The firm also manufactures items designed for women's and men's health, age management, weight loss, and immune system health. In all, Quantum offers about 60 different products sold individually as well as in "value packs" of related products such as its outdoor kit which offers insect repellant, sun block, insect bite treatment, and anti-itch cream. The company also sells anti-aging, cold sore, and immune support kits.

QLT Inc. company was founded in 1981 and is headquartered in Vancouver, Canada. QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, as well as OT-730, a prodrug of a beta adrenergic antagonist (a type of beta blocker) under investigation for the treatment of glaucoma.

Pharmavite's Nature Made brand of vitamins, mineral supplements, and herbal remedies are sold through major mass retailers and drugstore chains. Like all successful supplement makers, Pharmavite's product lines shift and adapt and new product development is key. It has entered the snack food segment with its SOYJOY nutrition bars and manufactures vitamins under the Olay brand. Pharmavite was founded in 1971 and acquired by Otsuka Pharmaceutical in 1989. Otsuka has since introduced the Nature Made vitamin brand to Japan. Pharmavite manufactures all of its products at its facilities in California.

SSCI, Inc. company provides research, analytical, and consulting services to the pharmaceutical and chemical industries. For its drugmaker customers, the R&D firm offers drug formulation, stabilization, engineering services, and regulatory consulting, all which allow pharmaceutical companies to speed up the development process, which can last as long as 15 years. SSCI's analysis services include moisture and organic vapor sorption and desorption studies, thermal analysis, and micromeritics, or the characterization of the surface of a solid. SSCI is a subsidiary of pharmaceutical services firm Aptuit.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.